Allopurinol-Induced Toxic Epidermal Necrolysis
- PMID: 38347997
- PMCID: PMC10861211
- DOI: 10.7759/cureus.52222
Allopurinol-Induced Toxic Epidermal Necrolysis
Abstract
Toxic epidermal necrolysis (TEN) is a rare and life-threatening cutaneous disease, frequently triggered by drugs. Allopurinol is one of the most frequent drugs associated with TEN, which implies detachment of a significant amount of the body surface area (BSA) and has a high morbidity and mortality associated with it. We present the case of a 68-year-old female with a recent diagnosis of hyperuricemia who started treatment with allopurinol. A week later, she presented to the emergency department with an extensive maculopapular exanthema with blisters and skin detachment. After the exclusion of other etiologies, the diagnosis of allopurinol-induced TEN was made, with 35% of BSA involvement. Due to the severity of the clinical condition, she was admitted to intensive care and treated with corticoids that had no response. So, she was started on immunoglobulins and transferred to a burn unit. She developed sepsis with multiorgan failure and required supportive treatment. She was discharged after a month, and physical rehabilitation was needed. This clinical case highlights the severity of allopurinol hypersensitivity that may happen and the importance of an accurate diagnosis and treatment for this rare disease.
Keywords: allopurinol; allopurinol hypersensitivity; stevens-johnson syndrome (sjs); toxic epidermal necrolysis (ten); toxicity.
Copyright © 2024, Perdigão et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Epidermal necrolysis: 60 years of errors and advances. Heng YK, Lee HY, Roujeau JC. Br J Dermatol. 2015;173:1250–1254. - PubMed
-
- Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis — diagnosis and treatment. Grünwald P, Mockenhaupt M, Panzer R, Emmert S. J Dtsch Dermatol Ges. 2020;18:547–553. - PubMed
-
- Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Stamp LK, Day RO, Yun J. Nat Rev Rheumatol. 2016;12:235–242. - PubMed